Arimidex to get 2nd indication as early breast cancer treatment.

The KFDA authorized Astra Zeneca's Arimidex (anastrozol) on April 4 for the early breast cancer treatment in addition to its original claims of the advancing breast cancer after menopause.

Arimidex, a 3rd generation of aromatase inhibitor, was indicated for the treatment of early breast cancer with estrogen receptor positive in addition to the advancing breast cancer that was already approv...